| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 02/27/2003 | WO2003016499A2 Combinatorial methods for inducing cancer cell death |
| 02/27/2003 | WO2003016498A2 Molecular interaction sites of rnase p rna and methods of modulating the same |
| 02/27/2003 | WO2003016496A2 Zinc finger binding domains for cnn |
| 02/27/2003 | WO2003016495A2 Transgenic rodents as animal models for modulation of b1 bradykinin receptor protein |
| 02/27/2003 | WO2003016493A2 Transporters and ion channels |
| 02/27/2003 | WO2003016491A2 Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
| 02/27/2003 | WO2003016490A2 Rna silencing suppression |
| 02/27/2003 | WO2003016489A2 Porcine leptin protein, antisense and antibody |
| 02/27/2003 | WO2003016483A2 METHOD OF LABELLING cRNAs FOR PROBING OLIGO-BASED MICROARRAYS |
| 02/27/2003 | WO2003016482A2 Methyltransferase genes and uses thereof |
| 02/27/2003 | WO2003016481A2 Novel human collagen proteins and polynucleotides encoding the same |
| 02/27/2003 | WO2003016478A2 G-protein coupled receptor polynucleotides and methods of use thereof |
| 02/27/2003 | WO2003016477A2 Insect or83b odorant receptor |
| 02/27/2003 | WO2003016474A2 Methods and compositions for use in selectively producing a protein in telomerase expressing cells |
| 02/27/2003 | WO2003016473A2 Bovine leptin protein, antisense and antibody |
| 02/27/2003 | WO2003016472A2 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/27/2003 | WO2003016471A2 Periostin-based diagnostic assays |
| 02/27/2003 | WO2003016468A2 Antagonistic anti-htnfsf13b human antibodies |
| 02/27/2003 | WO2003016466A2 ANTI-Aβ ANTIBODIES |
| 02/27/2003 | WO2003016465A2 Cell cycle regulator protein |
| 02/27/2003 | WO2003016464A2 Cancer specific oligosaccharide sequences and use thereof |
| 02/27/2003 | WO2003016354A2 Recombinant anti-plasmodium falciparum antibodies |
| 02/27/2003 | WO2003016349A1 A method of producing glucagon-like peptide 1(glp-1)7-36 and an glp-1 analogue |
| 02/27/2003 | WO2003016345A1 Regulation of human regulator of g-protein signaling |
| 02/27/2003 | WO2003016343A2 USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS |
| 02/27/2003 | WO2003016342A2 Tumor antigens for prevention and/or treatment of cancer |
| 02/27/2003 | WO2003016340A1 Derp1 and proderp1 allergen derivatives |
| 02/27/2003 | WO2003016339A1 A frog skin antibacterial peptide derivative |
| 02/27/2003 | WO2003016333A2 Virus coat protein/receptor chimeras and methods of use |
| 02/27/2003 | WO2003015915A1 Solid compositions for selective adsorption from complex mixtures |
| 02/27/2003 | WO2003015816A1 Immunomodulatory oligonucleotide formulations and methods for use thereof |
| 02/27/2003 | WO2003015812A2 Beta-amyloid-analogue-t-cell epitop vaccine |
| 02/27/2003 | WO2003015803A1 Cell compositions for use in the treatment of osteo-arthrosis, and method for producing the same |
| 02/27/2003 | WO2003015768A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015714A2 Compositions and therapeutic methods for viral infection |
| 02/27/2003 | WO2003015711A2 Combination motif immune stimulatory oligonucleotides with improved activity |
| 02/27/2003 | WO2003015708A2 Composition and method for treating hiv infection |
| 02/27/2003 | WO2003015707A2 Method for treating lung cancers |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015702A2 Epitopes of human immunodeficiency virus-1 |
| 02/27/2003 | WO2003015697A2 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | WO2003015689A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 02/27/2003 | WO2003015613A2 Molecular characteristics of non-small cell lung cancer |
| 02/27/2003 | WO2003015507A1 Development of transgenic model for interventions in neurodegenerative diseases |
| 02/27/2003 | WO2003015506A1 Propagation of human hepatoblastoma cell in non-human animals |
| 02/27/2003 | WO2003015505A2 An animal model exhibiting cancer, pulmonary emphysema and cardiomyopathy |
| 02/27/2003 | WO2003015500A2 Methods for the identification of inhibitors of phytochrome e expression or activity in plants |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003001178A3 Configurable dynamic three dimensional array |
| 02/27/2003 | WO2003000894A9 Polynucleotide vaccine |
| 02/27/2003 | WO2003000656A3 Antisense modulation of transforming growth factor beta receptor ii expression |
| 02/27/2003 | WO2002102986A3 Novel human transporter proteins and polynucleotides encoding the same |
| 02/27/2003 | WO2002102977A9 Characterization of a membrane estrogen receptor |
| 02/27/2003 | WO2002101356A3 Organellar proteomics including determination of targets for therapeutic intervention identified in the mitochondrial proteome using mass spectrometry |
| 02/27/2003 | WO2002101052A3 Salutaridinol 7-o-acetyltransferase and derivatives thereof |
| 02/27/2003 | WO2002100348A3 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 02/27/2003 | WO2002099037A3 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002094853A3 Antibodies specific for poly(ethylene glycol) |
| 02/27/2003 | WO2002092763A3 Intron associated with myotonic dystrophy type 2 and methods of use |
| 02/27/2003 | WO2002092134A8 Lentiviral vectors encoding clotting factors for gene therapy |
| 02/27/2003 | WO2002090496A3 Novel methods of directed evolution |
| 02/27/2003 | WO2002089657A3 Diagnostic markers of acute coronary syndromes and methods of use thereof |
| 02/27/2003 | WO2002086091A3 Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector |
| 02/27/2003 | WO2002086057A3 Process for genetic transformation and co-transformation of yeasts |
| 02/27/2003 | WO2002083871A3 Rapid and enzymeless cloning of nucleic acid fragments |
| 02/27/2003 | WO2002083064A3 A method of treating cancer |
| 02/27/2003 | WO2002081638A3 Prostate cancer expression profiles |
| 02/27/2003 | WO2002081634A3 Imaging nucleic acid delivery |
| 02/27/2003 | WO2002080851A3 Chimeric vaccines |
| 02/27/2003 | WO2002080845A3 Novel eps8 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002080844A3 Novel bgp compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002074957A3 Stress-responsive activator of p300 (strap) protein |
| 02/27/2003 | WO2002074930A3 Trans inteins for protein domain shuffling and biopolymerization |
| 02/27/2003 | WO2002074794A3 Compositions useful in gene therapy |
| 02/27/2003 | WO2002072846A3 Synthetic genes and bacterial plasmids devoid of cpg |
| 02/27/2003 | WO2002072814A3 Engineered baculoviruses and their use |
| 02/27/2003 | WO2002072017A3 Method of drug target validation |
| 02/27/2003 | WO2002072006A3 METHODS AND REAGENTS FOR IDENTIFYING COMPOUNDS AND MUTATIONS THAT MODULATE DOPAMINE β-HYDROXYLASE ACTIVITY |
| 02/27/2003 | WO2002071040A3 Use of infrared spectroscopy in genotypic analysis |
| 02/27/2003 | WO2002070709A3 Molecules for disease detection and treatment |
| 02/27/2003 | WO2002070564A3 The guinea pig proteinase-activated receptor 4 and its activating peptide |
| 02/27/2003 | WO2002069903A3 Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| 02/27/2003 | WO2002068651A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/27/2003 | WO2002068453A3 Methods and compositions for the construction and use of fusion libraries using computational protein design methods |
| 02/27/2003 | WO2002067669A3 Primordial germ cell-based germ line production of birds |
| 02/27/2003 | WO2002066656A3 Detection of protein conformation using a split ubiquitin reporter system |
| 02/27/2003 | WO2002066644A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/27/2003 | WO2002066629A8 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| 02/27/2003 | WO2002064172A3 Fhit gene therapy prevents tumor development in fhit-deficient mice |
| 02/27/2003 | WO2002061040A3 Gene delivery formulations and methods for treatment of ischemic conditions |
| 02/27/2003 | WO2002060951A3 Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| 02/27/2003 | WO2002059316A3 Human ion exchanger proteins and polynucleotides encoding the same |
| 02/27/2003 | WO2002059259A3 Methods for discovering secreted and transmembrane proteins |
| 02/27/2003 | WO2002057466A3 Processes and vectors for plastid transformation of higher plants |
| 02/27/2003 | WO2002057464A3 Method for the expression of biosynthetic genes in plant seeds using multiple expression constructs |
| 02/27/2003 | WO2002055725A3 Novel nucleic acids, methods and transformed cells for the modulation of gibberellin production |
| 02/27/2003 | WO2002055714A3 Human protease and polynucleotides encoding the same |
| 02/27/2003 | WO2002055555A3 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |